| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1500 | Cmx521 | Novel Inhibitor for RNA-Dependent RNA Polymerase of Norovirus |
|
| DCC1501 | Cn14_17 | Novel Potent Inhibitor of the HIV-1 Nucleocapsid Protein |
|
| DCC1502 | Cn-716 | Novel Zika virus (ZIKV) NS2B-NS3pro protease inhibitor |
|
| DCC1503 | cn-chalc4 | Novel blocker of binding of CXCL12 to CXCR4 |
|
| DCC1504 | Cng-10300 | Novel partial blocker of GluK1, with GluK2 being unaffected |
|
| DCC1505 | Cni103 | Novel potent and selective blocker of the calcineurin-NFAT interaction (KD=16nM), preventing acute lung injury, being a promising novel treatment for ARDS and other inflammatory diseases |
|
| DCC1506 | Cns1261 | N-methyl-D-aspartate (NMDA) receptor ligand, selectivity targeting the intrachannel PCP/ketamine/MK-801 site of NMDA receptor |
|
| DCC1507 | Cns-5161 | Novel and selective noncompetitive antagonist of the NMDA |
|
| DCC1508 | Cny-07 | Novel potent RIPK1/necroptosis ligand, penetrate the blood-brain barrier |
|
| DCC1509 | Cobimetinib Hemifumarate | Novel inhibitor of mitogen-activated protein kinase (MAPK) |
|
| DCC1510 | Coelenterazine E | Bioluminescent probe |
|
| DCC1511 | Coibamide A | Natural lariat depsipeptide, inhibiting VEGFA/VEGFR2 expression and suppressing tumor growth in glioblastoma xenografts, targeting Sec61 to prevent biogenesis of secretory and membrane proteins |
|
| DCC1512 | Col049 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1513 | Col050 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1514 | Col051 | Novel potent and selective inhibitor of the interaction between Hsp47 and collagen |
|
| DCC1515 | Colletochlorin B | Natural differentiation inducer of human promyelocytic leukemia cells |
|
| DCC1516 | Combretastatin | Inhibitor of tubulin polymerization, preventing cancer cells from producing microtubules |
|
| DCC1517 | combretastatin A-4p | Inhibitor of tubulin polymerization; vascular disrupting agent (VDA) |
|
| DCC1518 | Compound 8h | Inducer of G2/M-phase cell cycle arrest and cell death in cancer cell lines |
|
| DCC1519 | compound G | Dual inhibitor of phospholipid transfer protein and microsomal triglyceride transfer protein |
|
| DCC1520 | Compound H | Novel inducer of Klotho (KL) expression |
|
| DCC1521 | Conexipyrones A | Natural triketide pyrone, functioning as a sulfate shuttle and its sulfated derivative being accepted as donor molecules by the PAPS-independent arylsulfate sulfotransferase (ASST) Cpz4 to yield sulfated caprazamycin intermediate |
|
| DCC1522 | Conjugated Estrogens | A mixture of estrogen hormones used to treat menopause symptoms such as hot flashes and vaginal changes, and to prevent osteoporosis (bone loss) in menopausal women, being also used to replace estrogen in women with ovarian failure or other conditions tha |
|
| DCC1523 | Copper Probe Cf4 | Novel fluorescent copper probe |
|
| DCC1524 | Cor1-25 | Novel potent and selective melanocortin-4 receptor inhibitor, possessing 15-fold selectivity for the MC4R versus the MC3R |
|
| DCC1525 | Cor627 | Novel positive allosteric modulator of the GABA(B) receptor |
|
| DCC1526 | Cor628 | Novel positive allosteric modulator of the GABA(B) receptor |
|
| DCC1527 | Cordyheptapeptide A | Natural potent cytotoxic agent against multiple cancer cell lines, acting on cells as a protein synthesis inhibitor, targeting the eukaryotic translation elongation factor 1A (eEF1A), a target shared by other lipophilic cyclic peptide natural products |
|
| DCC1528 | Co-releasing Agent 5 | Novel photoCORM, exhibiting good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach in cancerous B16F10 cells |
|
| DCC1529 | Corrector C18 | Novel class I mutation corrector, rescuing CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis |
|
